Compare DHI & EW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DHI | EW |
|---|---|---|
| Founded | 1978 | 1958 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Industrial Specialties |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.8B | 48.9B |
| IPO Year | 1995 | 1999 |
| Metric | DHI | EW |
|---|---|---|
| Price | $148.36 | $90.80 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 14 | 21 |
| Target Price | ★ $166.08 | $96.37 |
| AVG Volume (30 Days) | 2.3M | ★ 4.3M |
| Earning Date | 04-21-2026 | 04-23-2026 |
| Dividend Yield | ★ 1.19% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 7.45 | 1.07 |
| Revenue | ★ $34,250,400,000.00 | $6,067,600,000.00 |
| Revenue This Year | $0.05 | $13.39 |
| Revenue Next Year | $5.85 | $9.81 |
| P/E Ratio | ★ $19.91 | $84.87 |
| Revenue Growth | N/A | ★ 11.55 |
| 52 Week Low | $131.75 | $72.30 |
| 52 Week High | $183.62 | $96.29 |
| Indicator | DHI | EW |
|---|---|---|
| Relative Strength Index (RSI) | 46.61 | 56.52 |
| Support Level | $145.45 | $81.19 |
| Resistance Level | $150.95 | $93.91 |
| Average True Range (ATR) | 4.02 | 1.87 |
| MACD | 0.16 | 0.34 |
| Stochastic Oscillator | 37.22 | 67.95 |
D.R. Horton is the largest homebuilder in the United States with operations in 126 markets across 36 states. D.R. Horton mainly builds single-family homes (over 90% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. The firm has majority ownership of Forestar Group, a publicly traded residential lot development company. D.R. Horton's headquarters are in Arlington, Texas.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.